NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Activation of the HIV promoter by radiation and drugs.

Zmudzka BZ, Beer JZ, Olvey KM, Strickland AG, Lee W, Jacobs ME; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 149 (abstract no. M.A.1229).

Food and Drug Administration, HFZ-114, Rockville, MD 20857, USA

OBJECTIVE: Several laboratories reported that HIV is activated by ultraviolet radiation (UV). We evaluated the HIV-activating potential of radiation exposures used in dermatology, oncology, in experimental AIDS treatment, for experimental blood product cleansing, and in cosmetology. Such exposures involve ultraviolet radiation in the A and B ranges (UVA and UVB), combined exposure to psoralens and UVA radiation (PUVA, including extracorporeal PUVA photopheresis), and ionizing radiation. METHODS: Induction of the HIV promoter activity was measured in cultures of HeLa cells stably transfected with the HIV promoter/chloramphenicol acetyl transferase (CAT) gene vector. The cells were exposed to selected treatments and 20 h later CAT activity was measured. Evaluation of the HIV-activating potential of different exposures was based on comparing the highest levels of HIV promoter induction. RESULTS: The results confirm that the HIV promoter is strongly activated by UVB or UVC but not by UVA radiation. The most effective fluence of UVB was 750 J/m(2); thus, the effective fluences are in the range of real life exposures. UVA in combination with 5-methoxypsoralen, 8-methoxypsoralen, or 4'-aminomethyl-4,5',8-trimethylpsoralen also strongly activated the promoter. The most effective fluences were inversely related to drug concentration. X rays had little or no effect in inducing the promoter. DISCUSSION AND CONCLUSIONS: HIV promoter is strongly activated in vitro by UVB and UVA + psoralens under conditions similar to those occurring in therapeutic and cosmetic, as well as environmental exposures. Further studies are needed to determine how the phenomena observed in vitro with the HIV promoter relate or contribute to the effects produced by similar exposures in the human body infected with the complete virus.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • Acquired Immunodeficiency Syndrome
  • Animals
  • Cats
  • Chloramphenicol O-Acetyltransferase
  • HIV
  • HIV Infections
  • HIV Long Terminal Repeat
  • HIV Seropositivity
  • Hela Cells
  • Humans
  • In Vitro
  • Methoxsalen
  • Pharmaceutical Preparations
  • Phototherapy
  • Promoter Regions (Genetics)
  • Psoralens
  • Radiation, Ionizing
  • Trioxsalen
  • Ultraviolet Rays
  • genetics
Other ID:
  • 1122991
UI: 102182792

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov